Jafron Biomedical Co.,Ltd. (SHE:300529)

Jafron Biomedical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	2,629	1,919	2,487	2,671	1,946	1,429
Other Revenue	3.42	3.42	4.54	4.5	4.64	2.61
Revenue	2,632	1,922	2,491	2,675	1,951	1,432
Revenue Growth (YoY)	34.86%	-22.84%	-6.88%	37.15%	36.24%	40.86%
Cost of Revenue	508.4	385.42	440.36	402.12	288	197.44
Gross Profit	2,124	1,537	2,051	2,273	1,663	1,234
Selling, General & Admin	878.62	793.36	838.78	729.46	587.45	537.15
Research & Development	243.74	245.38	253.91	173.77	80.76	68.45
Other Operating Expenses	65.79	24.61	33.72	39.56	28.24	22.39
Operating Expenses	1,190	1,054	1,124	949.55	697.27	629.88
Operating Income	933.73	482.98	926.66	1,324	965.51	604.5
Interest Expense	-61.99	-54.33	-36.04	-8.91	-	-
Interest & Investment Income	71.79	87.96	63.79	56.5	44.01	44.21
Currency Exchange Gain (Loss)	1.22	1.22	1.07	-0.81	-0.37	0.13
Other Non Operating Income (Expenses)	12.79	-2.12	-0.5	-5.34	-2.36	-0.16
EBT Excluding Unusual Items	957.55	515.71	954.97	1,365	1,007	648.67
Impairment of Goodwill	-25.61	-25.61	-6.26	-	-	-
Gain (Loss) on Sale of Investments	0.33	-	-0.01	0.01	-	-
Gain (Loss) on Sale of Assets	3.18	6.72	0.86	0.98	-	-
Asset Writedown	-1.48	-1.46	-1.61	-1.15	-0.48	-1.35
Other Unusual Items	42.78	25.66	68.85	42.14	25.64	23.96
Pretax Income	976.75	521.02	1,017	1,407	1,032	671.28
Income Tax Expense	182.64	95.3	135.86	211.38	158.95	102.59
Earnings From Continuing Operations	794.11	425.72	880.95	1,196	873	568.69
Minority Interest in Earnings	10.36	10.77	8.62	0.97	2.24	2.13
Net Income	804.47	436.49	889.56	1,197	875.24	570.82
Net Income to Common	804.47	436.49	889.56	1,197	875.24	570.82
Net Income Growth	82.93%	-50.93%	-25.67%	36.74%	53.33%	42.00%
Shares Outstanding (Basic)	794	794	794	803	796	793
Shares Outstanding (Diluted)	795	794	794	803	810	793
Shares Change (YoY)	-0.51%	-0.08%	-1.12%	-0.89%	2.22%	0.68%
EPS (Basic)	1.01	0.55	1.12	1.49	1.10	0.72
EPS (Diluted)	1.01	0.55	1.12	1.49	1.08	0.72
EPS Growth	83.87%	-50.89%	-24.83%	37.96%	50.00%	41.04%
Free Cash Flow	872.54	669.49	407.91	712	600.37	362.82
Free Cash Flow Per Share	1.10	0.84	0.51	0.89	0.74	0.46
Dividend Per Share	0.400	0.400	0.670	0.900	0.660	0.474
Dividend Growth	-40.30%	-40.30%	-25.56%	36.36%	39.33%	50.00%
Gross Margin	80.68%	79.95%	82.33%	84.97%	85.24%	86.21%
Operating Margin	35.48%	25.12%	37.19%	49.48%	49.49%	42.22%
Profit Margin	30.56%	22.71%	35.70%	44.73%	44.87%	39.87%
Free Cash Flow Margin	33.15%	34.83%	16.37%	26.61%	30.78%	25.34%
EBITDA	1,037	571.49	995.72	1,373	1,002	634.29
EBITDA Margin	39.39%	29.73%	39.97%	51.32%	51.38%	44.30%
D&A For EBITDA	103.09	88.51	69.07	49.25	36.73	29.79
EBIT	933.73	482.98	926.66	1,324	965.51	604.5
EBIT Margin	35.48%	25.12%	37.19%	49.48%	49.49%	42.22%
Effective Tax Rate	18.70%	18.29%	13.36%	15.02%	15.40%	15.28%
Revenue as Reported	2,632	1,922	2,491	2,675	1,951	1,432

Source: S&P Global Market Intelligence. Standard template. Financial Sources.